Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17924892 | 0.76 | MGLL (0.38) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL331187 | 0.75 | MGLL (0.41) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL13742892 | 0.75 | MGLL (0.41) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL11457779 | 0.74 | MGLL (0.42) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL17924891 | 0.73 | MGLL (0.35) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL17924834 | 0.73 | MGLL (0.35) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL17924943 | 0.73 | MGLL (0.35) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL31071892 | 0.71 | MGLL (0.35) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL17924921 | 0.70 | MGLL (0.38) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL708908 | 0.69 | MGLL (0.38) | MGLLGSK3AGSK3BGMNNALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 656 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240011011-A1 | BIOCATALYTICAL COMPOSITION | INOFEA GMBH (CH) | 2024-01-11 | — | — | US | claimed |
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | AMUNIX PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | claimed |
| EP-2494075-B1 | TEMPLATED NANOCONJUGATES | UNIV NORTHWESTERN (US) | 2018-04-04 | — | — | EP | claimed |
| US-20160168559-A1 | BIOCATALYTICAL COMPOSITION | INOFEA GMBH (CH) | 2016-06-16 | — | — | US | claimed |
| EP-3027750-A1 | BIOCATALYTICAL COMPOSITION | Inofea GmbH (CH) | 2016-06-08 | — | — | EP | claimed |
| WO-2015014888-A1 | BIOCATALYTICAL COMPOSITION | INOFEA GMBH (CH) | 2015-02-05 | — | — | WO | claimed |
| EP-2675481-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES AND METHODS OF PREPARATION | ImmunoGen, Inc. (US) | 2013-12-25 | — | — | EP | claimed |
| EP-2650309-A9 | CONJUGATE OF FOLATE AND ANTIBODY, PREPARATION METHOD AND USE THEREOF | Wuhan Huayao Biopharmaceutical Co., Ltd (CN) | 2013-12-11 | — | — | EP | claimed |
| EP-2650309-A1 | CONJUGATE OF FOLATE AND ANTIBODY, PREPARATION METHOD AND USE THEREOF | Wuhan Huayao Biopharmaceutical Co., Ltd (CN) | 2013-10-16 | — | — | EP | claimed |
| US-20130259882-A1 | Conjugate of Folate and Antibody Preparation Method and Use Thereof | ZHEJIANG JIANFENG HANSHENG BIOSCIENCES CO., LTD. (CN) | 2013-10-03 | — | — | US | claimed |
| EP-2494075-A2 | TEMPLATED NANOCONJUGATES | Northwestern University (US) | 2012-09-05 | — | — | EP | claimed |
| WO-2012112708-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES AND METHODS OF PREPARATION | IMMUNOGEN, INC. (US) | 2012-08-23 | — | — | WO | claimed |
| WO-2012020230-A1 | POLYMER PARTICLE | DNA TRACER TECHNOLOGIES LIMITED (GB) | 2012-02-16 | — | — | WO | claimed |
| WO-2011053940-A2 | TEMPLATED NANOCONJUGATES | NORTHWESTERN UNIVERSITY (US) | 2011-05-05 | — | — | WO | claimed |
| WO-2010063725-A2 | STRUCTURING PARTICLES INTO USEFUL STRUCTURES AND THEIR USE IN LIFE SCIENCE | MATTIASSON BO (SE) | 2010-06-10 | — | — | WO | claimed |
| WO-2009077438-A1 | METHOD FOR PREPARING PROTEIN CONJUGATES | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2009-06-25 | — | — | WO | claimed |
| US-20090098574-A1 | FUNCTIONALIZATION OF GOLD NANOPARTICLES WITH ORIENTED PROTEINS, APPLICATION TO THE HIGH-DENSITY LABELLING OF CELL MEMBRANES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) | 2009-04-16 | — | — | US | claimed |
| EP-2018559-A1 | FUNCTIONALIZATION OF GOLD NANOPARTICLES WITH ORIENTED PROTEINS. APPLICATION TO THE HIGH-DENSITY LABELLING OF CELL MEMBRANES | Centre National de la Recherche Scientifique (CNRS) (FR) | 2009-01-28 | — | — | EP | claimed |
| WO-2007122259-A1 | FUNCTIONALIZATION OF GOLD NANOPARTICLES WITH ORIENTED PROTEINS. APPLICATION TO THE HIGH-DENSITY LABELLING OF CELL MEMBRANES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2007-11-01 | — | — | WO | claimed |
| US-20030152932-A1 | Detection method using dissociated rolling circle amplification | QIAGEN GMBH (DE) | 2003-08-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | XPA, TXLNA, NGLY1 | MGLL 3726/4885GSK3A 3808/4885GSK3B 4105/4885 |
| US-20130259882-A1 | Conjugate of Folate and Antibody Preparation Method and Use Thereof | FOLR1, FOLR2, DHFR | MGLL 4810/4885GSK3A 4870/4885GSK3B 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.